Neuroblastoma Author

Antonia Palmer

Antonia is the founder of Neuroblastoma Canada and co-founder of Ac2orn. She volunteers with 3CTN, Network of Networks (N2), writes for the CNCF Parent Neuroblastoma Handbook, and is the Chair of the NANT Parent Advisory Council. Antonia has three sons, her oldest son Nate was diagnosed with stage IV high-risk neuroblastoma in 2009, had a CNS relapse in 2010 and he is now in long-term follow-up.

Posts by Antonia Palmer

DFMO

DFMO is an interesting drug, and one that is currently being considered for a future clinical trial in Canada for children with neuroblastoma. There is a great deal to understand about this drug – both in how it works and the process for opening up a clinical trial in Canada.

» CONTINUE READING

Posted in Relapse, Treatment | Tagged , , | Leave a comment

G-CSF and Neuroblastoma

In May 2015, neuroblastoma families became increasingly concerned about the use of G-CSF in treatment due to emerging research findings. This article reviews that research in hopes of providing some clarity.

» CONTINUE READING

Posted in Treatment | Tagged , | Leave a comment

MIBG Therapy for High-Risk Neuroblastoma

The science and understanding of MIBG therapy for high-risk neuroblastoma continues to evolve and change. This article reviews past research, current practices and future directions of the treatment.

» CONTINUE READING

Posted in Treatment | Tagged | 1 Comment

Counting the Cost

Your personal accountings of life tell a story and everyone’s numbers paint a different picture. This is an account of one 7-year-old boy in the battle against neuroblastoma cancer and what his numbers look like.

» CONTINUE READING

Posted in Awareness | Tagged , , , | 6 Comments

Interview with the Canadian Cancer Research Alliance (CCRA)

Neuroblastoma Canada interviews two authors from the CCRA’s report on the current state of financial investment into pediatric cancer research in Canada.

» CONTINUE READING

Posted in Investment | Tagged , , , | Leave a comment

Current and Future Strategies for Relapsed Neuroblastoma

Navigating the options available for relapsed treatment is incredibly difficult and is done without a set of established and well-entrenched guidelines.

» CONTINUE READING

Posted in Relapse, Treatment | Tagged , , , , , | 1 Comment

International Neuroblastoma Awareness Week

June 10-19, 2013 is International Neuroblastoma Awareness Week. A week dedicated to raise awareness about neuroblastoma cancer around the world.

» CONTINUE READING

Posted in Awareness | Tagged , | Leave a comment

Changes to the Chemotherapies Used in the COG Stem Cell Transplant Regimen

The chemotherapeutic drugs used during stem-cell transplant for high-risk neuroblastoma appear to be changing under the Children’s Oncology Group (COG) protocol.

» CONTINUE READING

Posted in News | Tagged , | Leave a comment

COG 2013 Blueprint for Neuroblastoma Research

In 2012, the Children’s Oncology Group (COG) Neuroblastoma Committee documented the important current and future research being done to further understand this perplexing disease.

» CONTINUE READING

Posted in Research, Treatment | Tagged , , , , | 2 Comments

MYCN Amplification, Possible Therapies, and BET Bromodomain Inhibition

A new post on the NB Globe website provides a detailed look at MYCN amplification in neuroblastoma and the emergence of a new therapy called BET bromodomain inhibition.

» CONTINUE READING

Posted in News, Research | Tagged , | Leave a comment

Back to Top